---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-003866"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:40:42.629142+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Capricor reports Q4 2022 net loss $7.7M ($0.31/share); expands Nippon Shinyaku deal to Japan for $12M upfront

## Summary
- Q4 2022 revenue $1.0M (Nippon Shinyaku upfront recognition) vs $0; net loss $7.7M vs $6.2M in Q4 2021.
- Full-year 2022 net loss $29.0M ($1.18/share) vs $20.0M ($0.87/share); cash $41.4M as of Dec 31, 2022.
- HOPE-3 Phase 3 trial for CAP-1002 in DMD >30% enrolled; interim analysis expected Q4 2023.
- Japan partnership with Nippon Shinyaku: $12M upfront, up to $89M milestones, double-digit net revenue share.
- Cash runway projected into Q4 2024, including $12M Japan upfront expected in Q1 2023.

## SEC filing metadata
- accession: 0001558370-23-003866
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837023003866/0001558370-23-003866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837023003866/capr-20230315x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-003866
- JSON: https://secwatch.observer/filing/0001558370-23-003866.json
- Plain text: https://secwatch.observer/filing/0001558370-23-003866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.